Study into prophylaxis treatment meets key endpoints
Results showed a clinically meaningful prevention of bleeds in people with severe haemophilia A
Read More
Tag: Swedish Orphan Biovitrum
Six new medicines leap towards EU approval
The recommendations include new treatments for cancer and intraocular pressure and prevention of uncomplicated flu.
Read More
Novo’s Refixia beats rival in head to head trial
Novo Nordisk’s Refixia has come out on top in a head to head study assessing its effect in patients with the bleeding disorder haemophilia B against Swedish Orphan Biovitrum’s recombinant factor IX-Fc fusion protein (rFIXFc).
Read More
NICE turnaround for AstraZeneca’s COPD drug Daxas
AstraZeneca’s Daxas is now likely to be routinely available on the NHS to patients with chronic obstructive pulmonary disease (COPD), after new evidence helped persuade cost regulators that the drug is value for money in this setting.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
